RT Journal Article
SR Electronic
T1 Robust methylation-based classification of brain tumors using nanopore sequencing
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.06.21252627
DO 10.1101/2021.03.06.21252627
A1 Kuschel, Luis P.
A1 Hench, Jürgen
A1 Frank, Stephan
A1 Hench, Ivana Bratic
A1 Girard, Elodie
A1 Blanluet, Maud
A1 Masliah-Planchon, Julien
A1 Misch, Martin
A1 Onken, Julia
A1 Czabanka, Marcus
A1 Karau, Philipp
A1 Ishaque, Naveed
A1 Hain, Elisabeth G.
A1 Heppner, Frank
A1 Idbaih, Ahmed
A1 Behr, Nikolaus
A1 Harms, Christoph
A1 Capper, David
A1 Euskirchen, Philipp
YR 2021
UL http://medrxiv.org/content/early/2021/03/08/2021.03.06.21252627.abstract
AB DNA methylation-based classification of cancer provides a comprehensive molecular approach to diagnose tumors. In fact, DNA methylation profiling of human brain tumors already profoundly impacts clinical neuro-oncology. However, current implementations using hybridization microarrays are time-consuming and costly. We recently reported on shallow nanopore whole-genome sequencing for rapid and cost-effective generation of genome-wide 5-methylcytosine profiles as input to supervised classification using random forests complemented by a medium-resolution copy number profile derived from the same raw data. Here, we demonstrate that this approach allows to discriminate a wide spectrum of primary brain tumors using public reference data of 82 distinct tumor entities. We developed a pseudo-probability score as a confidence score for interpretation in a clinical context. Using bootstrap sampling in a discovery cohort of N = 56 cases, we find that a minimum set of 1,000 random CpG features is sufficient for high-confidence classification by ad hoc random forests for most cases and demonstrate robustness across laboratories with matching results in 13/13 cases. When applying the confidence score threshold to an independent validation series (N = 111), the method demonstrated 100% specificity for the remaining 93 cases. In a prospective benchmarking (N = 15), median time to results was 21.1 hours. In conclusion, nanopore sequencing allows robust and rapid methylation-based classification across the full spectrum of brain tumors. The integrated confidence score facilitates possible clinical implementation, while requiring further prospective evaluation.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialU1111-1239-3456Funding StatementThe study was funded by the Brain Tumour Charity (UK) - GN-000694Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The local ethics committee (Charité Universitätsmedizin Berlin, Berlin, Germany; EA2/041/18) approved generation of prospective data in the context of this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe current nanoDx classification and analysis pipeline https://gitlab.com/pesk/nanoDx (version v.0.2.1 was used for preprocessing of all sequencing data) and the source code for the outlined RF implementation and to reproduce all analyses and figures in this manuscript https://gitlab.com/pesk/nanoBenchmark will be publicly available upon publication. Raw sequencing data from the discovery cohort will be deposited at the European Genome-phenome archive (accession tba). Methylation microarray raw data and methylation calls from the validation cohort will be deposited at ArrayExpress (accession tba).